Syquant Capital Sas Buys Shares of 192,722 Oculis Holding AG $OCS

Syquant Capital Sas purchased a new stake in shares of Oculis Holding AG (NASDAQ:OCS) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 192,722 shares of the company’s stock, valued at approximately $3,849,000. Oculis makes up about 0.5% of Syquant Capital Sas’ investment portfolio, making the stock its 18th biggest position.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Aventura Private Wealth LLC bought a new position in Oculis in the 4th quarter valued at approximately $80,000. Bosun Asset Management LLC bought a new stake in Oculis during the 2nd quarter worth approximately $378,000. Marshall Wace LLP acquired a new position in Oculis in the 2nd quarter valued at approximately $393,000. Geode Capital Management LLC raised its stake in shares of Oculis by 27.7% during the second quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after acquiring an additional 6,384 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in shares of Oculis by 2.2% during the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock valued at $786,000 after acquiring an additional 878 shares during the last quarter. Institutional investors and hedge funds own 22.30% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Oculis in a research note on Thursday, January 22nd. Stifel Nicolaus upped their price target on Oculis from $40.00 to $50.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. HC Wainwright increased their price target on Oculis from $42.00 to $44.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Lifesci Capital started coverage on Oculis in a research note on Wednesday, December 3rd. They issued an “outperform” rating and a $55.00 price objective on the stock. Finally, Needham & Company LLC boosted their target price on shares of Oculis from $36.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.86.

Oculis Stock Down 0.0%

Oculis stock opened at $24.99 on Friday. The company has a market capitalization of $1.45 billion, a PE ratio of -11.01 and a beta of 0.29. Oculis Holding AG has a 12-month low of $14.00 and a 12-month high of $30.68. The firm’s fifty day moving average is $27.44 and its 200 day moving average is $22.42. The company has a quick ratio of 5.96, a current ratio of 5.96 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.08). Oculis had a negative net margin of 8,173.41% and a negative return on equity of 62.12%. The company had revenue of $0.50 million during the quarter, compared to the consensus estimate of $0.14 million. As a group, sell-side analysts predict that Oculis Holding AG will post -2.09 EPS for the current fiscal year.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.